Akzo Nobel Past Earnings Performance
Past criteria checks 3/6
Akzo Nobel's earnings have been declining at an average annual rate of -12.2%, while the Chemicals industry saw earnings declining at 12.2% annually. Revenues have been growing at an average rate of 2.1% per year. Akzo Nobel's return on equity is 12.9%, and it has net margins of 6.3%.
Key information
-12.24%
Earnings growth rate
-9.65%
EPS growth rate
| Chemicals Industry Growth | 1.60% |
| Revenue growth rate | 2.07% |
| Return on equity | 12.90% |
| Net Margin | 6.26% |
| Next Earnings Update | 22 Jul 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 30
AKZA: Merger With Axalta And Mixed Views Will Shape Next Phase
Akzo Nobel’s analyst price target has been lifted from about €49.30 to €55.00. Analysts cited updated revenue growth and margin assumptions, along with recent Street targets in the €55 to €61 range, as support for the higher fair value estimate.
Narrative Update • Jun 16
AKZA: Merger Execution And Downgrade Reset Will Shape Fairly Valued Shares
Akzo Nobel's analyst price target has inched up to about €61.70 from roughly €61.18, as analysts factor in slightly higher fair value estimates and updated assumptions for discount rate, revenue growth and P/E. This follows mixed recent research that includes a resumed Buy rating and several price target cuts and downgrades.Narrative Update • Jun 02
AKZA: Margin Delivery And Downgrade Reset Will Shape Fairly Valued Repricing
Akzo Nobel's analyst price target has been cut by around €1 to €61, as analysts factor in more cautious assumptions on revenue growth and profitability following recent target reductions and downgrades from several major banks. Analyst Commentary Recent Street research on Akzo Nobel clusters around a series of target cuts and rating downgrades, with most analysts reworking their valuation frameworks to reflect more cautious assumptions on revenue growth and profitability.Narrative Update • May 02
AKZA: Margin Execution Is Expected To Support Repricing After Recent Downgrades
Akzo Nobel's updated analyst price target edges lower to about €62.60, as analysts factor in Street target cuts and downgrades, a slightly higher discount rate, and a more conservative future P/E assumption, despite using stronger revenue growth and profit margin inputs. Analyst Commentary Recent Street research on Akzo Nobel has focused on resetting expectations, with several firms lowering price targets and issuing downgrades.Narrative Update • Apr 17
AKZA: Margin Delivery Is Expected To Support Repricing After Recent Downgrades
Akzo Nobel's analyst price target has been trimmed by about €1.35. This reflects analysts' updated assumptions for slightly softer revenue growth and valuation multiples, partly balanced by a small uplift in expected profit margins.
New Narrative • Apr 16
Merger Synergies And Cost Programs Will Create A More Powerful Coatings Leader
Catalysts About Akzo Nobel Akzo Nobel is a global paints and coatings company serving decorative, industrial, automotive, marine, aerospace and packaging customers. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 03
AKZA: Rebased Earnings And Margins Are Expected To Support Upside Repricing
Akzo Nobel's analyst fair value estimate has been trimmed by €2 to €65, as analysts factor in a series of recent downgrades and lower price targets, along with updated assumptions for growth, margins and future P/E levels. Analyst Commentary Recent Street research on Akzo Nobel presents a mix of cautious and constructive views, with several downgrades and price target cuts offset by at least one upward adjustment to fair value.New Narrative • Apr 02
Cost Synergies And Portfolio Pruning Will Shape A Steady Long Term Coatings Platform
Catalysts About Akzo Nobel Akzo Nobel is a global paints and coatings company supplying decorative paints and performance coatings to customers across construction, industrial and transportation end markets. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 20
AKZA: Rebased Earnings Assumptions Will Support Upside Repricing Potential
Akzo Nobel's updated analyst price target has shifted modestly to €67.00, as analysts factor in a slightly higher discount rate, more conservative revenue growth and profit margin assumptions, and recalibrated P/E expectations despite mixed recent research views on the stock. Analyst Commentary Recent research on Akzo Nobel reflects a mix of optimism around upside potential and caution around execution risk, which together help explain the updated €67.00 price target.Analysis Article • Feb 15
We Think You Should Be Aware Of Some Concerning Factors In Akzo Nobel's (AMS:AKZA) Earnings
Akzo Nobel N.V.'s ( AMS:AKZA ) healthy profit numbers didn't contain any surprises for investors. We believe that...Narrative Update • Feb 05
AKZA: Axalta Merger Will Expand Scale And Recast Earnings Potential
Narrative Update The analyst price target for Akzo Nobel is updated to €68.12 from €69.65, reflecting mixed research views. Some analysts cite more measured expectations around the Axalta merger, muted coatings growth and a modest synergy timeline, while others maintain higher targets closer to €75 supported by their own assessments.Narrative Update • Jan 18
AKZA: Axalta Merger Will Reshape Scale And Earnings Profile
Analysts have nudged their fair value estimate for Akzo Nobel to €69.65 from €68.94, reflecting updated assumptions around revenue growth, margins and the Axalta merger, which align with recent Street price target moves between €59 and €75. Analyst Commentary Recent Street research around Akzo Nobel and its merger with Axalta provides a mixed but useful set of signals to consider when thinking about valuation, execution risk and growth potential.Analysis Article • Jan 12
Akzo Nobel (AMS:AKZA) Could Be At Risk Of Shrinking As A Company
When researching a stock for investment, what can tell us that the company is in decline? When we see a declining...Analysis Article • Dec 05
Is Akzo Nobel (AMS:AKZA) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Oct 22
Why Investors Shouldn't Be Surprised By Akzo Nobel N.V.'s (AMS:AKZA) P/E
With a price-to-earnings (or "P/E") ratio of 25.2x Akzo Nobel N.V. ( AMS:AKZA ) may be sending bearish signals at the...Analysis Article • Oct 09
Are Investors Undervaluing Akzo Nobel N.V. (AMS:AKZA) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Akzo Nobel fair value estimate is €105 Akzo Nobel's €59.94...Analysis Article • Aug 31
Is Akzo Nobel (AMS:AKZA) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 18
Is Now An Opportune Moment To Examine Akzo Nobel N.V. (AMS:AKZA)?
ENXTAM:AKZA 1 Year Share Price vs Fair Value Explore Akzo Nobel's Fair Values from the Community and select yours Let's...Analysis Article • Jul 17
Akzo Nobel N.V.'s (AMS:AKZA) Price In Tune With Earnings
When close to half the companies in the Netherlands have price-to-earnings ratios (or "P/E's") below 19x, you may...
New Narrative • Nov 19
Steady Streamlining And Strategic Expansion Ignite A Brighter Future
Efficiency programs and workforce reductions are set to bolster net margins through significant cost savings.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Akzo Nobel makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 9,931 | 622 | 2,918 | 274 |
| 31 Dec 25 | 10,158 | 636 | 2,969 | 274 |
| 30 Sep 25 | 10,405 | 59 | 3,036 | 296 |
| 30 Jun 25 | 10,526 | 415 | 3,045 | 296 |
| 31 Mar 25 | 10,684 | 467 | 3,120 | 296 |
| 31 Dec 24 | 10,711 | 542 | 3,091 | 296 |
| 30 Sep 24 | 10,621 | 565 | 3,048 | 270 |
| 30 Jun 24 | 10,694 | 592 | 3,071 | 270 |
| 31 Mar 24 | 10,651 | 534 | 2,992 | 270 |
| 31 Dec 23 | 10,668 | 447 | 2,962 | 270 |
| 30 Sep 23 | 10,745 | 411 | 2,976 | 258 |
| 30 Jun 23 | 10,866 | 309 | 2,976 | 258 |
| 31 Mar 23 | 10,978 | 303 | 2,983 | 258 |
| 31 Dec 22 | 10,846 | 362 | 2,939 | 258 |
| 30 Sep 22 | 10,643 | 540 | 2,864 | 230 |
| 30 Jun 22 | 10,191 | 616 | 2,766 | 230 |
| 31 Mar 22 | 9,849 | 758 | 2,661 | 230 |
| 31 Dec 21 | 9,587 | 823 | 2,610 | 230 |
| 30 Sep 21 | 9,393 | 805 | 2,618 | 238 |
| 30 Jun 21 | 9,259 | 866 | 2,599 | 238 |
| 31 Mar 21 | 8,735 | 741 | 2,547 | 238 |
| 31 Dec 20 | 8,530 | 637 | 2,579 | 238 |
| 30 Sep 20 | 8,563 | 544 | 2,595 | 262 |
| 30 Jun 20 | 8,685 | 481 | 2,677 | 262 |
| 31 Mar 20 | 9,149 | 567 | 2,764 | 262 |
| 31 Dec 19 | 9,276 | 517 | 2,833 | 262 |
| 30 Sep 19 | 9,342 | 477 | 2,929 | 264 |
| 30 Jun 19 | 9,270 | 463 | 2,918 | 264 |
| 31 Mar 19 | 9,265 | 354 | 3,028 | 264 |
| 31 Dec 18 | 9,256 | 400 | 3,044 | 264 |
| 30 Sep 18 | 9,231 | 393 | 3,005 | 270 |
| 30 Jun 18 | 9,324 | 365 | 3,068 | 270 |
| 31 Mar 18 | 9,411 | 426 | 3,050 | 270 |
| 31 Dec 17 | 9,612 | 439 | 3,107 | 270 |
| 30 Sep 17 | 6,022 | 107 | 2,329 | 257 |
| 30 Jun 17 | 7,203 | 272 | 2,603 | 257 |
| 31 Mar 17 | 8,381 | 417 | 2,888 | 257 |
| 31 Dec 16 | 9,434 | 534 | 3,138 | 257 |
| 30 Sep 16 | 14,300 | 1,032 | 4,158 | 347 |
| 30 Jun 16 | 14,460 | 1,031 | 4,194 | 347 |
| 31 Mar 16 | 14,698 | 1,051 | 4,253 | 347 |
| 31 Dec 15 | 14,859 | 973 | 4,279 | 347 |
| 30 Sep 15 | 14,817 | 772 | 4,295 | 363 |
Quality Earnings: AKZA has a large one-off gain of €357.0M impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: AKZA's current net profit margins (6.3%) are higher than last year (4.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKZA's earnings have declined by 12.2% per year over the past 5 years.
Accelerating Growth: AKZA's earnings growth over the past year (33.2%) exceeds its 5-year average (-12.2% per year).
Earnings vs Industry: AKZA earnings growth over the past year (33.2%) exceeded the Chemicals industry 32.3%.
Return on Equity
High ROE: AKZA's Return on Equity (12.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:47 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akzo Nobel N.V. is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Katie Richards | Barclays |
| Jennifer Barker | Barclays |
| Robert Bate | Barclays |